Newly-released Large Molecule Bioanalytical Testing Service industry analysis report by Future Market Insights reveals that global sales of Large Molecule Bioanalytical Testing Market in 2022 were held at US$ 1.3 Billion. With a CAGR of 12.1% from 2023 to 2033, the market is projected to reach US$ 4.7 Billion by 2033. Clinical Phase is expected to generate significant revenue and is projected to grow at a CAGR of 10.9% from 2023 to 2033.
| Attribute | Details |
|---|---|
| Global Market Size (2023) | US$ 1.5 Billion |
| Global Market Size (2033) | US$ 4.7 Billion |
| Global Market Size CAGR (2023 to 2033) | 12.1% |
| USA Market Size CAGR (2023 to 2033) | 12.3% |
| Key Companies Profiled |
|
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per the Large Molecule Bioanalytical Testing Service industry research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2018 to 2022, market value of the Large Molecule Bioanalytical Testing Service industry increased at around 11.9% CAGR, wherein, countries such as the USA, China, Japan, United kingdom and South Korea held significant share in the global market.
The increase in demand for forward-looking and high-grade large molecule bioanalytical testing services is expected to propel the market forward. Reduced time to market, increased regulatory observation, and a high risk of product failure are a few of the factors driving the demand for large molecule bioanalytical testing services. Owing to this, the Large Molecule Bioanalytical Testing Service market is projected to grow at a CAGR of 12.1% over the coming 10 years.
Because of rising healthcare expenditures, there is a greater need for high-quality care. The demand for analytical testing is developing in response to new pharmaceutical product advancements. Due to increased competition in the healthcare business and rising pricing concerns, many companies are turning to outsourcing services for analytical testing.
The demand for analytical testing has increased as research and development activities for new medication development, combination products, and other complex medicines have increased.
With the prevalence of HIV, infectious illnesses, and other disorders, the demand for bioanalytical testing services has shot up in the recent past. Furthermore, enhanced government actions to control the spread of infectious diseases like Corona and the Ebola virus are expected to assist the business. As a result, the market is expected to grow throughout the assessment period.
Throughout the projection period, increased research activities and the presence of a vast pipeline of peptides, biologics, and amino acid-based compounds are expected to move the market ahead. Bioanalysis of large molecules also involves the utilization of highly skilled professionals as well as analytical gear and infrastructure.
Principal Consultant
With a CAGR of 12.3% during the projected period, Large Molecule Bioanalytical Testing Service revenue is expected to grow at a significant pace in North America. Because of the rising frequency of numerous chronic diseases and the growing use of large-molecule medicines as an alternative to small molecules, the United States has the largest market share.
According to the International Diabetic Federation Report 2019, the United States has a diabetic population of 49 million geriatrics, which has resulted in an increase in demand for bioanalysis of new peptide therapies such as glucagon-like peptide 1. As a result, the market is likely to grow throughout the forecast period. Furthermore, the presence of large firms in the region aided market expansion.
As one of the main production hubs for highly dependable, complicated, and high-end pharmaceuticals, the USA accounted for a significant share of the global market in 2022. The market is likely to be driven by rapid technology improvements and increasing demand for bioanalytical testing services. Furthermore, because of the country's developing healthcare business, biopharmaceutical companies are focusing on the USA market.
The market in the United kingdom is expected to reach a valuation of US$ 180.6 Million by 2033. Growing with a CAGR of 12.9% in the forecast period, the market in the country is projected to garner an absolute dollar opportunity of around US$ 127 Million.
In Japan, the market is expected to grow at a CAGR of 10.8% from 2023 to 2033, reaching around US$ 161 Million by 2033. The market in the country is expected to gross an absolute dollar opportunity of US$ 104 Million during the forecast period.
The market in South Korea is expected to reach a valuation of around US$ 123 Million by 2033, growing at a CAGR of 12.6% from 2023 to 2033. The market in the country is expected to witness an absolute dollar opportunity of around US$ 85 Million.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The clinical segment is expected to grow at a CAGR of 10.9%. Based on the study phase, the market is segmented into preclinical and clinical. The rising frequency of chronic diseases and the growing demand for clinical trials in developing countries are likely to propel the segment forward.
The market through Antidrug Antibodies (ADA) is expected to grow at a CAGR of 11.8% during the forecast period. Large-molecule drug development is aided by ADA assays. Antibodies against large molecule medications, such as antibody or protein therapies, are produced by the immune system. As a result, ADAs can be detected using ADA tests. Patients who create an antibody response will have a variety of reactions, ranging from life-threatening to no clinical implications. This can lead to anaphylactic shock, allergic responses, or autoimmunity, among other things.
Pharmacokinetic expert services are carried out in accordance with GCP specifications as well as international regulatory rules. Moreover, clinical trials for biologics and biosimilars include a trial to measure the concentration of this drug in healthy volunteers.
The ELISA or MSD platform is used to offer this service. A commonly utilized immunoassay for the detection of significant in vitro pharmacokinetic research is ELISA. In line with the chemical construction and principle of operation of drug substances, antibody sensitivity in pharmacokinetic immunoanalysis should always be fixed.
The key players operating in the Large Molecule Bioanalytical Testing Services Market include Covance, IQVIA, Syneos Health, SGS SA, Toxikon, Intertek Group plc, Pace Analytical Services LLC, ICON Plc, Charles River Laboratories, and Thermo Fisher Scientific.
Few of the recent developments of key Large Molecule Bioanalytical Testing Service providers are as follows:
Similarly, recent developments related to companies in the Large Molecule Bioanalytical Testing Services have been tracked by the team at Future Market Insights, which are available in the full report.
The market is valued at US$ 1.5 billion in 2023.
The growth potential of the market is 12.1% through 2033.
The South Korea market is expected to expand at a CAGR of 12.6% through 2033.
Covance, IQVIA, and Syneos Health are the top players.
Key players are introducing new production facilities.
1. Executive Summary | Large Molecule Bioanalytical Testing Services Market 1.1. Global Market Outlook 1.2. Summary of Statistics 1.3. Key Market Characteristics & Attributes 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage 2.2. Market Definition 3. Market Risks and Trends Assessment 3.1. Risk Assessment 3.1.1. COVID-19 Crisis and Impact on Large Molecule Bioanalytical Testing Services 3.1.2. COVID-19 Impact Benchmark with Previous Crisis 3.1.3. Impact on Market Value (US$ Million) 3.1.4. Assessment by Key Countries 3.1.5. Assessment by Key Market Segments 3.1.6. Action Points and Recommendation for Suppliers 3.2. Key Trends Impacting the Market 3.3. Formulation and Product Development Trends 4. Market Background 4.1. Large Molecule Bioanalytical Testing Services Market, by Key Countries 4.2. Opportunity Assessment (US$ Million) 4.2.1. Total Available Market 4.2.2. Serviceable Addressable Market 4.2.3. Serviceable Obtainable Market 4.3. Market Scenario Forecast 4.3.1. Demand in optimistic Scenario 4.3.2. Demand in Likely Scenario 4.3.3. Demand in Conservative Scenario 4.4. Investment Feasibility Analysis 4.4.1. Investment in Established Markets 4.4.1.1. In Short Term 4.4.1.2. In Long Term 4.4.2. Investment in Emerging Markets 4.4.2.1. In Short Term 4.4.2.2. In Long Term 4.5. Forecast Factors - Relevance & Impact 4.5.1. Top Companies Historical Growth 4.5.2. Growth in Automation, By Country 4.5.3. Large Molecule Bioanalytical Testing Services Adoption Rate, By Country 4.6. Market Dynamics 4.6.1. Market Driving Factors and Impact Assessment 4.6.2. Prominent Market Challenges and Impact Assessment 4.6.3. Opportunities 4.6.4. Prominent Trends in the Global Market & Their Impact Assessment 5. Key Success Factors 5.1. Manufacturers’ Focus on Low Penetration High Growth Markets 5.2. Banking on with Segments High Incremental Opportunity 5.3. Peer Benchmarking 6. Global Demand Analysis 2015 to 2021 and Forecast, 2022 to 2032 6.1. Historical Market Analysis, 2015 to 2021 6.2. Current and Future Market Projections, 2022 to 2032 6.3. Y-o-Y Growth Trend Analysis 7. Global Value Analysis 2015 to 2021 and Forecast, 2022 to 2032 7.1. Historical Market Value (US$ Million) Analysis, 2015 to 2021 7.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Analysis 2015 to 2021 and Forecast 2022 to 2032, By Phase 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis By Phase, 2015 to 2021 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Phase, 2022 to 2032 8.3.1. Preclinical 8.3.1.1. With Antibody 8.3.1.2. Without Antibody 8.3.2. Clinical 8.4. Market Attractiveness Analysis By Phase 9. Global Analysis 2015 to 2021 and Forecast 2022 to 2032, By Type 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis By Type, 2015 to 2021 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Type, 2022 to 2032 9.3.1. Pharmacokinetics 9.3.2. ADA 9.3.3. Other Types 9.4. Market Attractiveness Analysis By Type 10. Global Analysis 2015 to 2021 and Forecast 2022 to 2032, By Test Type 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis By Test Type, 2015 to 2021 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Test Type, 2022 to 2032 10.3.1. ADME 10.3.2. PK 10.3.3. PD 10.3.4. Bioavailability 10.3.5. Bioequivalence 10.3.6. Other Test Types 10.4. Market Attractiveness Analysis By Test Type 11. Global Analysis 2015 to 2021 and Forecast 2022 to 2032, By Therapeutic Area 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis By Therapeutic Area, 2015 to 2021 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Therapeutic Area, 2022 to 2032 11.3.1. Oncology 11.3.2. Infectious Diseases 11.3.3. Cardiology 11.3.4. Neurology 11.3.5. Other End-users 11.4. Market Attractiveness Analysis By Therapeutic Area 12. Global Analysis 2015 to 2021 and Forecast 2022 to 2032, By Region 12.1. Introduction 12.2. Historical Market Size (US$ Million) Analysis By Region, 2015 to 2021 12.3. Current Market Size (US$ Million) & Analysis and Forecast By Region, 2022 to 2032 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. Asia Pacific 12.3.5. Middle East and Africa (MEA) 12.4. Market Attractiveness Analysis By Region 13. North America Analysis 2015 to 2021 and Forecast 2022 to 2032 13.1. Introduction 13.2. Pricing Analysis 13.3. Historical Market Value (US$ Million) Trend Analysis By Market Taxonomy, 2015 to 2021 13.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032 13.4.1. By Country 13.4.1.1. USA 13.4.1.2. Canada 13.4.1.3. Rest of North America 13.4.2. By Phase 13.4.3. By Type 13.4.4. By Therapeutic Area 13.4.5. By Test Type 13.5. Market Attractiveness Analysis 13.5.1. By Country 13.5.2. By Phase 13.5.3. By Type 13.5.4. By Therapeutic Area 13.5.5. By Test Type 14. Latin America Analysis 2015 to 2021 and Forecast 2022 to 2032 14.1. Introduction 14.2. Pricing Analysis 14.3. Historical Market Value (US$ Million) Trend Analysis By Market Taxonomy, 2015 to 2021 14.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032 14.4.1. By Country 14.4.1.1. Brazil 14.4.1.2. Mexico 14.4.1.3. Rest of Latin America 14.4.2. By Phase 14.4.3. By Type 14.4.4. By Therapeutic Area 14.4.5. By Test Type 14.5. Market Attractiveness Analysis 14.5.1. By Country 14.5.2. By Phase 14.5.3. By Type 14.5.4. By Therapeutic Area 14.5.5. By Test Type 15. Europe Analysis 2015 to 2021 and Forecast 2022 to 2032 15.1. Introduction 15.2. Pricing Analysis 15.3. Historical Market Value (US$ Million) Trend Analysis By Market Taxonomy, 2015 to 2021 15.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032 15.4.1. By Country 15.4.1.1. Germany 15.4.1.2. France 15.4.1.3. United kingdom 15.4.1.4. Italy 15.4.1.5. Benelux 15.4.1.6. Nordic Countries 15.4.1.7. Rest of Europe 15.4.2. By Phase 15.4.3. By Type 15.4.4. By Therapeutic Area 15.4.5. By Test Type 15.5. Market Attractiveness Analysis 15.5.1. By Country 15.5.2. By Phase 15.5.3. By Type 15.5.4. By Therapeutic Area 15.5.5. By Test Type 16. Asia Pacific Analysis 2015 to 2021 and Forecast 2022 to 2032 16.1. Introduction 16.2. Pricing Analysis 16.3. Historical Market Value (US$ Million) Trend Analysis By Market Taxonomy, 2015 to 2021 16.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032 16.4.1. By Country 16.4.1.1. China 16.4.1.2. Japan 16.4.1.3. South Korea 16.4.1.4. Rest of Asia Pacific 16.4.2. By Phase 16.4.3. By Type 16.4.4. By Therapeutic Area 16.4.5. By Test Type 16.5. Market Attractiveness Analysis 16.5.1. By Country 16.5.2. By Phase 16.5.3. By Type 16.5.4. By Therapeutic Area 16.5.5. By Test Type 17. Middle East and Africa Analysis 2015 to 2021 and Forecast 2022 to 2032 17.1. Introduction 17.2. Pricing Analysis 17.3. Historical Market Value (US$ Million) Trend Analysis By Market Taxonomy, 2015 to 2021 17.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032 17.4.1. By Country 17.4.1.1. GCC Countries 17.4.1.2. South Africa 17.4.1.3. Turkey 17.4.1.4. Rest of Middle East and Africa 17.4.2. By Phase 17.4.3. By Type 17.4.4. By Therapeutic Area 17.4.5. By Test Type 17.5. Market Attractiveness Analysis 17.5.1. By Country 17.5.2. By Phase 17.5.3. By Type 17.5.4. By Therapeutic Area 17.5.5. By Test Type 18. Key Countries Analysis 2015 to 2021 and Forecast 2022 to 2032 18.1. Introduction 18.1.1. Market Value Proportion Analysis, By Key Countries 18.1.2. Global Vs. Country Growth Comparison 18.2. US Analysis 18.2.1. Value Proportion Analysis by Market Taxonomy 18.2.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.2.2.1. By Phase 18.2.2.2. By Type 18.2.2.3. By Therapeutic Area 18.2.2.4. By Test Type 18.3. Canada Analysis 18.3.1. Value Proportion Analysis by Market Taxonomy 18.3.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.3.2.1. By Phase 18.3.2.2. By Type 18.3.2.3. By Therapeutic Area 18.3.2.4. By Test Type 18.4. Mexico Analysis 18.4.1. Value Proportion Analysis by Market Taxonomy 18.4.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.4.2.1. By Phase 18.4.2.2. By Type 18.4.2.3. By Therapeutic Area 18.4.2.4. By Test Type 18.5. Brazil Analysis 18.5.1. Value Proportion Analysis by Market Taxonomy 18.5.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.5.2.1. By Phase 18.5.2.2. By Type 18.5.2.3. By Therapeutic Area 18.5.2.4. By Test Type 18.6. Germany Analysis 18.6.1. Value Proportion Analysis by Market Taxonomy 18.6.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.6.2.1. By Phase 18.6.2.2. By Type 18.6.2.3. By Therapeutic Area 18.6.2.4. By Test Type 18.7. France Analysis 18.7.1. Value Proportion Analysis by Market Taxonomy 18.7.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.7.2.1. By Phase 18.7.2.2. By Type 18.7.2.3. By Therapeutic Area 18.7.2.4. By Test Type 18.8. Italy Analysis 18.8.1. Value Proportion Analysis by Market Taxonomy 18.8.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.8.2.1. By Phase 18.8.2.2. By Type 18.8.2.3. By Therapeutic Area 18.8.2.4. By Test Type 18.9. BENELUX Analysis 18.9.1. Value Proportion Analysis by Market Taxonomy 18.9.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.9.2.1. By Phase 18.9.2.2. By Type 18.9.2.3. By Therapeutic Area 18.9.2.4. By Test Type 18.10. UK Analysis 18.10.1. Value Proportion Analysis by Market Taxonomy 18.10.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.10.2.1. By Phase 18.10.2.2. By Type 18.10.2.3. By Therapeutic Area 18.10.2.4. By Test Type 18.11. Nordic Countries Analysis 18.11.1. Value Proportion Analysis by Market Taxonomy 18.11.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.11.2.1. By Phase 18.11.2.2. By Type 18.11.2.3. By Therapeutic Area 18.11.2.4. By Test Type 18.12. China Analysis 18.12.1. Value Proportion Analysis by Market Taxonomy 18.12.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.12.2.1. By Phase 18.12.2.2. By Type 18.12.2.3. By Therapeutic Area 18.12.2.4. By Test Type 18.13. Japan Analysis 18.13.1. Value Proportion Analysis by Market Taxonomy 18.13.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.13.2.1. By Phase 18.13.2.2. By Type 18.13.2.3. By Therapeutic Area 18.13.2.4. By Test Type 18.14. South Korea Analysis 18.14.1. Value Proportion Analysis by Market Taxonomy 18.14.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.14.2.1. By Phase 18.14.2.2. By Type 18.14.2.3. By Therapeutic Area 18.14.2.4. By Test Type 18.15. GCC Countries Analysis 18.15.1. Value Proportion Analysis by Market Taxonomy 18.15.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.15.2.1. By Phase 18.15.2.2. By Type 18.15.2.3. By Therapeutic Area 18.15.2.4. By Test Type 18.16. South Africa Analysis 18.16.1. Value Proportion Analysis by Market Taxonomy 18.16.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.16.2.1. By Phase 18.16.2.2. By Type 18.16.2.3. By Therapeutic Area 18.16.2.4. By Test Type 18.17. Turkey Analysis 18.17.1. Value Proportion Analysis by Market Taxonomy 18.17.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.17.2.1. By Phase 18.17.2.2. By Type 18.17.2.3. By Therapeutic Area 18.17.2.4. By Test Type 18.17.3. Competition Landscape and Player Concentration in the Country 19. Market Structure Analysis 19.1. Market Analysis by Tier of Companies 19.2. Market Concentration 19.3. Market Share Analysis of Top Players 19.4. Market Presence Analysis 19.4.1. By Regional footprint of Players 19.4.2. Product footprint by Players 20. Competition Analysis 20.1. Competition Dashboard 20.2. Competition Benchmarking 20.3. Competition Deep Dive 20.3.1. Covance, Inc. 20.3.2. IQVIA 20.3.3. Syneos Health 20.3.4. Charles River Laboratory International 20.3.5. ICON Plc 20.3.6. SGS SA 20.3.7. Toxikon 20.3.8. Intertek Group plc 20.3.9. Pace Analytical Services LLC 20.3.10. PPD, INC. 21. Assumptions and Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports
Large Molecule Bioanalytical Testing Services Market
